Industry Supported Breakfast Symposium: Learn More About New Corlanor®: What Nurses Need to Know
Nancy M. Albert, PhD, CCNS, CHFN, FAHA; Cleveland Clinic,  Cleveland, OH

Presented by Amgen

Product Theater: Furosemide 2.0: A Convenient, Comfortable Alternative to Intravenous Furosemide
Pieter Muntendam, MD, President, scPharmaceuticals                                                                                                                                                               

Approximately $10b is spent annually in the US alone on clinical diuresis -inducing diuresis with iv furosemide in an emergency room, observation unit and hospital. A novel formulation of Furosemide is under development for subcutaneous administration for administration by a wearable patch pump. This would provide convenient iv-like diuresis where and when needed.

Presented by scPharmaceuticals

Product Theater: AdaptivCRT: A New Standard in CRT
John Scherschel, MD, Clinical Cardiac Electrophysiologist                                                                                                                                                                    
AdaptivCRT is a dynamic, physiologic pacing algorithm which enhances cardiac resynchronization therapy (CRT) by adjusting CRT parameters automatically with changes in patient activity levels and conduction status. Dr. Scherschel will discuss CRT patient selection criteria, operation of the algorithm and review the latest clinical evidence available. Dr. Scherschel specializes in heart rhythm management including complex catheter ablation, intra-cardiac echo, and device management including pacemakers, defibrillators, and cardiac resynchronization therapy at Prairie Heart Institute, St. John’s Hospital in Springfield, Illinois.

Presented by Medtronic

Product Theater: Offer HOPE to your advanced heart failure patients - the HeartMate II® Left Ventricular Assist Device (LVAD)
Aditya Bansal, MD, Cardiothoracic Surgeon from Ochsner Medical Center                                                                                                                                            

Learn about the benefits of LVAD therapy for advanced heart failure. Get an update on ROADMAP study results which supports use of HeartMate II in functionally limited non-inotrope dependent heart failure patients. Learn when and what patients refer to for HeartMate II LVAD and find out how to talk to patients about HeartMate II LVAD. 

Presented by Thoratec

Industry Supported Dinner Symposium: Implantable Hemodynamic Monitoring: Putting It into Practice
Chairperson: Sara Paul, DNP, FNP, CHFN / Director of the Heart Function Clinic, Catawba Valley Cardiology, Conover, NC                                
Brent Lampert, DO, The Ohio State University, Columbus, OH
Laura Yamokoski, MSN, RN, CCRC, CHFN,  The Ohio State University, Columbus, OH
Irene Cooper, RN, Brigham and Women’s Hospital, Boston, MA                                                                                                                                                              
The CardioMEMS™  HF System is the first FDA-approved heart failure (HF) monitor, that, when used by clinicians to monitor their NYHA Class III HF patients, includingthe difficult to treat HFpEF patients, has been shown to significantly reduce HF hospitalizations and improve their quality of life.In this dinner program, you will learn the principles of hemodynamic monitoring in HF and how to translate this into the use of pulmonary artery (PA) pressure monitoring in order to better manage your heart failure patients. HF Centers utilizing the CardioMEMS HF System will present their workflow and implementation strategies from both an academic and private community practice setting. In addition, lessons learned will be shared.

Objectives:

• Discuss hemodynamics in heart failure and how it applies to pulmonary artery pressure monitoring
• Describe the use of pulmonary artery pressure management in academic and community settings
• Identify and discuss lessons learned in pulmonary artery pressure management

Presented by St. Jude Medical

Industry Supported Breakfast Symposium: Heart to Heart: Achieving Best Outcomes When Caring For Your African American Patients
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH, Tulane Heart and Vascular Institute, New Orleans, LA
Karol Harshaw-Ellis, MSN, DNP, GNP, A/ACNP-BC, Duke University Health System/Heart Center

Heart failure affects approximately 6 million Americans and is the most common diagnosis for hospitalization in patients over 65 years. African Americans are disproportionately affected by heart failure, with a higher prevalence at an early age than whites. Moreover, African Americans with heart failure have higher rates of hospital readmissions and even death when compared to their white counterparts. Health disparities in cardiovascular diseases and care persist and involve social determinants of health and many socioeconomic factors. Health care providers must utilize advances in evidence-based therapeutics and multiple strategies for managing patients with this life threatening illness. Clinicians treating African Americans, and others, must identify and eliminate barriers to attaining treatment goals. By implementing a team approach and a continuum of-care concept, the individual patient, the heart failure population, and healthcare economics will benefit.

Objectives:

• Identify heart failure (HF) epidemiology and pathophysiology in African Americans (AAs)
• Describe HF guidelines and evidence-based pharmacotherapy in AAs
• Review evidence from major clinical outcome trials specific to AAs
• Recognize how team-based care can be effective in reducing health disparities

Supported by an educational grant from Arbor Pharmaceuticals LLC.                                                                                                  

Product Theater: Exploring Risk Reduction in Thrombosis
Uri Elkayam, MD, Professor of Medicine Professor of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA

This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultants are paid speakers for Janssen Pharmaceuticals, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen. 

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

Supported by: Janssen Pharmaceuticals, Inc.

Industry Supported Dinner Symposium: The ABCs and 123s of Sleep
J. Thomas Heywood, MD, FACC, Scripps Clinic, La Jolla, CA
Robin J. Trupp, RN, PhD, ACNP-BC, CHFN, FAHA, University of Illinois, Chicago, IL

Objectives:

• Review and define commonly used terms, abbreviations and therapies used in sleep medicine. 
• Review and define regulations and requirements for reimbursement of sleep tests and initiated therapies. 
• Present and discuss an inpatient algorithm for the recognition of sleep apnea in patients with heart failure.

Presented by ResMed

Industry Supported Breakfast Symposium: Clinical Challenge: Hyperkalemia in the HF Patient
Marilyn Prasun, RN, PhD, CHFN, CCNS, CNL, FAHA, Memorial Medical Center, Springfield, IL

Hyperkalemia is a common occurrence in patients with congestive heart failure, particularly when renal failure coexists. Patients with congestive heart failure very commonly, particularly in the advanced stages of the disease, have moderate renal insufficiency, either due to specific heart failure-related renal perfusion changes or as the result of renal involvement from the same processes having caused the heart failure, as is the case with diabetes. The correct use of medications will often effectively deter clinically relevant hyperkalemia. Heart Failure Nurses are often responsible for monitoring, educating, and in some cases prescribing these medications. In this session the speaker will: describe the danger of hyperkaleimia in the HF patient and identify precipitating factors; contrast the mechanism of actions of organic polymer resins and new therapies; and identify potassium containing foods and understanding their dietary role.

Objectives:

• Describe the danger of hyperkalemia in the HF patient and identify precipitating factors. 
• Contrast the mechanism of actions of organic polymer resins and new therapies for hyperkalemia.
• Identify potassium containing foods and the importance of understanding their dietary role.

Supported by an Educational Grant from Zs Pharmaceuticals

Industry Supported Lunch Symposium: Corlanor®: Presenting a New Treatment Option

Hector O. Ventura, MD, FACC, FACP, FRCPE, Ochsner Medical Center, New Orleans, LA

Supported by Amgen